-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

622.O3.6 622. Lymphomas: Translational - Non-Genetic: New Approaches and Models for Improving Lymphoma Therapies

Symposia: Lymphomas: Translational - Non-Genetic Program: Oral and Poster Abstracts
Type: Oral
Hematology Disease Topics & Pathways:
Research, Fundamental Science, Combination therapy, Translational Research, Non-Hodgkin lymphoma, Lymphomas, Clinical Practice (Health Services and Quality), Elderly, B Cell lymphoma, T Cell lymphoma, Diseases, Immune mechanism, Indolent lymphoma, Treatment Considerations, Immunology, Lymphoid Malignancies, Biological Processes, Technology and Procedures, Molecular biology, Study Population, Human, Pathogenesis, Omics technologies
Monday, December 9, 2024: 4:30 PM-6:00 PM
Marriott Grand Ballroom 11-13 (Marriott Marquis San Diego Marina)
Moderators:
Maher K. Gandhi, PhD, FRACP, FRCPath, University of Queensland Diamantina Institute and Cynthia K. Hahn, MD, PhD, ARRAY(0xefea9e0)
Disclosures:
No relevant conflicts of interest to declare.

This session will describe novel molecular pathways in lymphoma and how we might be able to target these with new agents or combinations of agents.
4:30 PM

Ted B. Piorczynski, PhD1, Saagar Jain2*, Manuel Pazos II, MS, BS3*, Yun Kyoung Tiger, MD, PhD4, Seda S. Tolu, MD5 and Jennifer E. Amengual, MD6

1Division of Hematology and Oncology, Columbia University Irving Medical Center, New York, NY
2Columbia University Vagelos College of Physicians and Surgeons, Columbia University Irving Medical Center, New York
3Columbia University Medical Center, NEW YORK, NY
4Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ
5Division of Hematology & Oncology, Columbia University Irving Medical Center, New York City, NY
6Division of Hematology & Oncology, Columbia University Irving Medical Center, New York

4:45 PM

Dmitry Kazantsev, MSc, PhD1*, Eva Pokorna, Ing, CSc2*, Kristýna Nožičková, MD3*, Alexandra Dolníková, MSc2*, Nicol Renešová, MSc2*, Liliana Tuskova, MD1*, Marek Trněný, MD, CSc4,5 and Pavel Klener6,7*

1Institute of Pathological Physiology, First Faculty of Medicine, Charles University, Prague, Czech Republic
2Institute of Pathological Physiology, Charles University, First Faculty of Medicine, Prague, Czech Republic
3First Faculty of Medicine, Institute of Pathological Physiology, Charles University, Prague, Czech Republic
4Charles University, First Faculty of Medicine, Prague, Czech Republic
5First Dept. of Internal Medicine- Hematology, University General Hospital, Prague, Czech Republic
61st Department of Medicine – Department of Hematology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic
7Institute of Pathological Physiology, First Faculty of Medicine, Charles University, Praha 2, Czech Republic

5:00 PM

Anastasia Iatrou1,2*, Marco Patrone3*, Ioannis Sarrigeorgiou4*, Nikolaos Pechlivanis2*, David Graham Oscier5, Alexandra Traverse-Glehen, MD, PhD6*, Raphael Sandaltzopoulos1*, Niki Stavroyianni7*, Andreas Agathangelidis8*, Georgios Petrakis9*, Triantafyllia Koletsa9*, Peggy Lymberi4*, Paolo Ghia10,11, Anastasia Chatzidimitriou2,12*, Massimo Degano3* and Kostas Stamatopoulos2,12*

1Department of Molecular Biology and Genetics, Democritus University of Thrace, Alexandroupolis, Greece
2Institute of Applied Biosciences, Centre for Research and Technology Hellas, Thessaloniki, Greece
3Università Vita-Salute San Raffaele and Biocrystallography Group, Division of Immunology, Transplantation and Infectious Diseases, IRCCS San Raffaele Scientific Institute, Milan, Italy
4Immunology Laboratory, Immunology Department, Hellenic Pasteur Institute, Athens, Greece
5Department of Haematology, Royal Bournemouth Hospital, Bournemouth, United Kingdom
6Service de Pathologie Sud, Hospices Civils de Lyon, Pierre-Bénite, France
7Department of Hematology - BMT Unit, G. Papanicolaou Hospital, Thessaloniki, Greece
8School of Biology, National and Kapodistrian University of Athens, Athens, Greece
9Pathology Department, Medical School, Aristotle University of Thessaloniki, Thessaloniki, Greece
10Division of Experimental Oncology, B cell neoplasia, IRCCS Ospedale San Raffaele, Milan, Italy
11Medical School, Università Vita-Salute San Raffaele, Milano, Italy
12Department of Molecular Medicine and Surgery, Karolinska Institute, Stockholm, Sweden

5:15 PM

Etienne Leveille, MD1*, Eden Bramson1*, Mark E Robinson, PhD1*, Thierry Bertomeu, PhD2*, Andrew Chatr-Aryamontri, PhD2*, Shalin Kothari, MD1* and Markus Müschen, MD1

1Center of Molecular and Cellular Oncology, Yale University, New Haven, CT
2The ChemoGenix pooled CRISPR screening platform of the Institute for Research in Immunology and Cancer, Université de Montréal, Montréal, QC, Canada

5:30 PM

Zhuangzhuang Shi, PhD1*, Wenxing Jiang2*, Zhaoming Li2*, Wei-Hua Chen3* and Mingzhi Zhang, MD2

1Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China
2The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China
3College of Life Science and Technology, Huazhong University of Science and Technology, Wuhan, China

5:45 PM

Michael P Randall, MD1, Huimin Geng, PhD2*, Lingjing Chen, PhD1*, Aishwarya Ballapuram3*, Chitoh Yung1*, Ming Lu1*, Gregory Chin4*, Michael Mish, PhD4*, Jamie Bates, PhD4* and James L. Rubenstein, MD, PhD5

1Hematology/Oncology, Department of Medicine, University of California, San Francisco, San Francisco, CA
2Department of Laboratory Medicine, University of California, San Francisco, San Francisco, CA
3University of California, San Francisco, San Francisco, CA
4Oncology Sciences, Gilead, Foster City, CA
5Hematology/Oncology, Department of Medicine, Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA

*signifies non-member of ASH